Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.


This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.

Full Title of Study: “A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2018


  • Biological: GX-188E, GX-I7
    • Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
  • Biological: GX-188E, Imiquimod
    • 1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.

Arms, Groups and Cohorts

  • Experimental: GX-188E, GX-I7
    • GX-188E + GX-I7
  • Experimental: GX-188E, Imiquimod
    • GX-188E + Imiquimod

Clinical Trial Outcome Measures

Primary Measures

  • Ratio of subjects who have histopathological regression of cervical lesions to CIN 1 or less in HPV 16 or 18-associated CIN3 subjects.
    • Time Frame: at week 20

Secondary Measures

  • Ratio of subjects with clearance of HPV 16 or 18 and histopathological regression of cervical lesions to CIN 1 or less.
    • Time Frame: at week 20, and week 36
  • The change of cytology of uterine cervix compared to baseline.
    • Time Frame: at screening, week 12, week 20, and week 36
  • Flt-3L concentrations in blood samples.
    • Time Frame: at week 14, week 20, and week 36.

Participating in This Clinical Trial

Inclusion Criteria

  • Able and willing to comply with all study procedures and voluntarily signs informed consent form. – Female subjects age 19-50 years. – HPV 16 and/or 18 positive. – Colposcopy is satisfactory based on visualization of the entire squamocolumnar junction and the upper limit of the entire aceto-white or suspected CIN disease area – Histopathologically diagnosed with Cervical Intraepithelial Neoplasia 3, CIN 3. Exclusion Criteria:

  • Pregnancy or breastfeeding – History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded). – Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV). – Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study.

Gender Eligibility: Female

Minimum Age: 19 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Seoul St. Mary’s Hospital
  • Collaborator
    • Genexine, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jongsup Park, Professor – Seoul St. Mary’s Hospital
  • Overall Contact(s)
    • Jong-Sup Park, +82-2-2258-2724,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.